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Abstract: Interrupted time series (ITS) analysis is being increasingly used in epidemiology. 
Despite its growing popularity, there is a scarcity of guidance on power and sample size con-
siderations within the ITS framework. Our aim of this study was to assess the statistical power 
to detect an intervention effect under various real-life ITS scenarios. ITS datasets were created 
using Monte Carlo simulations to generate cumulative incidence (outcome) values over time. 
We generated 1,000 datasets per scenario, varying the number of time points, average sample 
size per time point, average relative reduction post intervention, location of intervention in the 
time series, and reduction mediated via a 1) slope change and 2) step change. Performance 
measures included power and percentage bias. We found that sample size per time point had 
a large impact on power. Even in scenarios with 12 pre-intervention and 12 post-intervention 
time points with moderate intervention effect sizes, most analyses were underpowered if the 
sample size per time point was low. We conclude that various factors need to be collectively 
considered to ensure adequate power for an ITS study. We demonstrate a means of providing 
insight into underlying sample size requirements in ordinary least squares (OLS) ITS analysis 
of cumulative incidence measures, based on prespecified parameters and have developed Stata 
code to estimate this.
Keywords: epidemiology, interrupted time series, sample size, power, bias
Introduction
Interrupted time series (ITS) analysis is being increasingly used in epidemiology.1–3 
It is an accessible and intuitive method that can be straightforward to implement and 
has considerable strengths.4 A common application is when population-level repeated 
measures of an outcome and/or exposure are available over time, both before and 
after some well-defined intervention such as a health policy change1,2,5 or a naturally 
occurring event of interest.6,7
Despite the substantial growth in the use of ITS methods, relatively little practical 
guidance has been developed in terms of methodological standards within the ITS 
framework,1,3 including a scarcity of guidance on required sample size. Sample size 
planning is often a key component of designing a study and should be conducted prior 
to analysis,8 although this is an aspect very often overlooked in ITS studies, with many 
being underpowered.9
Information on the power associated with various numbers of repeated measures 
of an outcome (ie, time points) has been previously reported,10 with rules of thumb 
concerning the minimum number of pre- and post-intervention time points needed, 
such as 3,3 6,11 8,12 and ≥10.9 However, researchers seeking to aggregate patient-level 
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data into a population-level time series to conduct an ITS are 
confronted with the practical issue of considering a suitable 
underlying sample size of subjects/patients per aggregate 
time point.13 Although longer time series have been shown 
to have more power than shorter time series, it seems rea-
sonable to propose that ITS analyses (even those with many 
time points) with only a small number of subjects per time 
point may contain so much noise as to render it improbable 
of detecting a true impact of an intervention under study. 
Although the ITS method has many strengths, if a given 
analysis is not adequately powered it may lead to publication 
of weak and spurious findings.14,15
Given this paucity of guidance on sample size calcula-
tion, our aim in this study was to use a simulation approach 
to estimate power in an ITS analysis case study of repeated 
measures of cumulative incidence generated from routinely 
collected health care data. We aimed to quantify the power 
available in relation to the underlying sample size per time 
point, while varying a number of other key parameters of 
interest. Furthermore, we set out to make available Stata 
code to be readily usable by epidemiologists as a tool to 
generate estimates of required sample size for similar ITS 
applications.
Methods
Study design
We used Monte Carlo simulations, the strengths of which 
have been well described previously.16,17 Briefly, simulation 
studies involve generating data with known characteristics 
defined by prespecified input parameter values. Consequently, 
because the truth regarding these characteristics is known, 
it is possible to empirically evaluate the performance of a 
given statistical model when fitted to the simulated data.18,19
Aims
Our aim was to describe the power associated with the mean 
sample size per time point to detect a change in 1) level and 
2) trend in an outcome (cumulative incidence) following a 
defined intervention in the ITS framework, using ordinary 
least squares (OLS) regression. We considered a range of 
values for various other factors such as total number of time 
points, effect size, and location of intervention in the time 
series. We set out to apply the methods within the context of 
a specific case study using a recent ITS analysis, where we 
evaluated the impact of a UK National Institute for Health 
and Care Excellence (NICE) technology appraisal on the 
cumulative incidence of joint replacement within the Clinical 
Practice Research Datalink (CPRD).20
ItS scenarios
There are many factors within an OLS ITS framework 
that could conceivably influence the power to detect the 
impact of an intervention. Although the following is not 
an exhaustive list, we here describe the main factors that 
we investigated:
1. Total number of time points in the time series, N 
( Figure 1A and B): as described in the “Introduction” 
section, the ITS approach relies on repeated observations 
of an outcome event over time, usually at equally spaced 
intervals such as days, weeks, months, quarters, or years. 
We investigated nine values for the total number of time 
points (N), ranging from 6 to 50.
2. Number of subjects per time point, n (Figure 1C and D): 
the sample size per time point will impact the accuracy 
of outcome estimates and hence the dispersion of a given 
time series. It is therefore an important factor influencing 
the power to detect an “interruption”. We investigated 11 
values for n, ranging from approximately 150 to 5,700 
patients per time point, which for our specific case study 
corresponded to a mean number of outcome events per 
time point that ranged from 5 to 200 (Supplementary 
materials).
3. Nature of intervention impact (Figure 1A–D): the impact 
of an intervention can be modeled as a “step” change 
in the level of outcome and/or a “slope” change in the 
trend of outcome.4,21 More complex realities can be 
incorporated such as multiple interventions, waning or 
delayed effects, and nonlinear responses.2,21 However, 
for the purpose of the current work, we only considered 
intervention effects mediated through either 1) a step 
change or 2) a slope change.
4. Effect size, ie, magnitude of intervention impact: one 
of the assumptions of ITS analysis is that the pre-
intervention level and trend of outcome can be used 
to predict post-intervention counterfactual estimates, 
ie. expected values of the outcome in the time period 
after the intervention had pre-intervention level/trend 
of outcome continued uninterrupted.2,21 The impact of 
intervention can then be expressed as the difference 
between the estimated counterfactual outcome value 
for a given post-intervention time point vs the estimated 
modeled outcome value for the same time point using 
the observed data.22 In practice, this has often been done 
for the midpoint of the post-intervention period to yield 
an average post-intervention change.5,20,23 We therefore 
used the magnitude of this average post-intervention 
change expressed as a relative % to express effect size, 
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defined for mid-time series interventions as the step or 
slope change resulting in a –15%, –34%, –50%, and 
–75% reduction.
5. Mean pre-intervention level and trend of outcome: the 
absolute pre-intervention level of outcome is an impor-
tant factor. For example, a relative 50% reduction in a 
common outcome should be easier to detect than a rela-
tive 50% reduction in a rare outcome. Furthermore, a 
pre-intervention trend in outcome may exist, which may 
also have an effect on power. We therefore considered 
two parameters: the mean pre-intervention outcome 
value (defined using the pre-intervention midpoint) in 
conjunction with a pre-intervention trend parameter. In 
main analyses, we only explored scenarios (based on 
our prior CPRD study20), where mean pre-intervention 
cumulative incidence was 3.5% and there was either 1) 
no pre-intervention trend (for step change scenarios) or 
2) an upward trend (for slope change scenarios), as shown 
in Figure 1. We scaled trend parameters according to N 
so that absolute pre-intervention values were constant 
across all mid-time series intervention scenarios. Exact 
parameter values for these are provided in the “Supple-
mentary materials” section.
6. Location of intervention in time series: location of 
intervention in the time series may also have an impact 
on power as this will affect the balance in the number 
of pre-intervention and post-intervention time points to 
be modeled. Locations investigated were at one-third, 
midway, and two-thirds from the beginning of the time 
series. For trend change scenarios in our case study, we 
used the same pre-intervention and post-intervention 
trends when investigating early/late interventions as per 
the corresponding midway intervention setting within 
each N scenario (Supplementary materials).
data-generating process
Data were generated using Stata v15.2 (StataCorp LLC, 
College Station, TX, USA), the general principles of which 
have been described elsewhere.24 Empty time series datasets 
were created of length N (total number of time points). 
Three ITS variables were inserted: time point identifier 
(integer), post-intervention indicator (binary), and post-
intervention time point identifier (integer).21 The time 
point identifier was created first, then used in combination 
with the “location of intervention” parameter to generate 
the other two ITS variables. The underlying sample size 
for each time point (n
t
) was then simulated from a normal 
distribution with mean n (a key parameter of interest; 11 
values investigated) and SD of n/3. The number of outcome 
events occurring at each time point was then drawn as a 
Figure 1 Example simulation scenarios for (A) less time points vs (B) more time points; (C) smaller sample size per time point vs (D) larger sample size per time point.
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binomial random variate (n
t
, p
t
), where n
t
 represents the 
sample size and p
t
 is the probability of outcome. p
t
 was a 
linear function defined using the ITS variables in combina-
tion with other scenario-specific parameter values (equa-
tion included in the “Supplementary materials” section). 
The number of events per time point and n
t
 were used to 
derive the cumulative incidence time series. A total of 
1,000 Monte Carlo repetitions were carried out for each 
unique scenario.
Methods of analysis
A segmented linear regression model was fitted to each cre-
ated dataset. This took the form of model (1) for step change 
scenarios and model (2) for slope change scenarios:
(1) Y
t
=β
0
 + β
1
*time point
t
 + β
2
*intervention_indicator
t
 + e
(2) Y
t
=β
0
 + β
1
*time point
t
 + β
3
*post_intervention_timepoint
t
 + e
where Y
t
 is the value of outcome at time point t. b
0
 estimates 
the level of the outcome just before the beginning of the time 
series. b
1
 estimates the pre-intervention trend, b
2
 estimates 
the change in level between the time point immediately 
before vs after the intervention, and b
3
 estimates the change 
in trend occurring immediately after the intervention. e is 
the error term.
Estimands
The target of inference was the change in outcome following 
a defined intervention, specifically testing the null hypoth-
esis of no change (ie, β
2
=0 [model 1] or β
3
=0 [model 2]). 
The outcome at each time point was a proportion, which in 
our case study was the 5-year cumulative incidence of joint 
replacement in rheumatoid arthritis patients.20
Performance
The coefficients, standard error, and P-values from these 
models were stored, and the empirical power to reject the 
null hypothesis of no post-intervention change was calculated 
as the proportion of simulations, where the P-value for the 
intervention variable coefficient (step/slope change) was 
<0.05.19,24,25 This was represented graphically as contour plots 
across scenarios according to N and n. For the convenience 
of comparison, additional presentation was made for power 
according to different effect size and location scenarios while 
keeping N constant (N=28). In addition, the percentage bias19 
of the regression coefficients was calculated for midway step 
and slope change scenarios (while keeping N constant), which 
is defined as follows:
 
Percentage bias
Average estimate across simulations
True parame
=
- ter value
True parameter value






*100
 
Sensitivity analysis
To explore the impact of pre-intervention level of outcome, 
we repeated main analyses investigating power for slope and 
step changes while keeping N constant (N=28) but varying 
pre-intervention level from 3.5% to 8% and then to 20%. 
Stata program
Although we based the current analyses on a case study 
exploring a range of parameter values adapted from our 
prior CPRD study as specified earlier,20 we also developed 
a Stata program (Supplementary materials) with associated 
documentation (Supplementary materials) to provide a 
ready-to-use means for assessing power associated with any 
valid list of (nine) input parameter values as described in the 
“Supplementary materials” section.
Results
Results from our case study are presented in the following 
paragraphs describing the impact of N and n on power within 
several ITS scenarios (Figure 2A and 2B). Results from analy-
ses exploring different effect sizes (whilst keeping N constant) 
are presented in Figures 3A and 3B. Although the main results 
pertained to a setting where the mean pre-intervention level 
of outcome for mid-time series interventions was 3.5%, the 
Stata program developed can be used to explore alternative 
input parameter values (Supplementary materials).
Slope change
As expected, power increased as N and/or n increased 
( Figure 2A) and as effect sizes became larger (Figure 3A). 
Results for different N and n combinations for each effect 
size investigated are provided in the “Supplementary materi-
als” section. These indicated that nearly all mid-time series 
intervention scenarios with a large effect size (–75%) had 
at least 80% power when there were >24 total time points, 
even when there was a very small sample size per time 
point (approximately 150 subjects, which in this case-study, 
corresponded to only five outcome events per time point). 
However, when the effect size was small (–15%) then to 
achieve 80% power an analysis had to either contain a large 
N or very large n (Supplementary materials). While keeping 
other factors constant (effect size =-34% and N=28), power 
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was greater in scenarios with mid-time series interventions, 
with comparably less power in scenarios with earlier/later 
interventions (Figure 4A). The percentage bias in model 
coefficients was small, and this trended toward zero as sample 
size increased (Figure 5).
Step change
Similar to slope change scenarios, power increased as N 
and n became larger (Figure 2B) or as the effect size was 
larger (Figure 3B). Generally, there was less power in step 
change scenarios than in corresponding slope change sce-
narios ( Figure 2A and B), with nearly all mid-time series 
intervention scenarios being inadequately powered when the 
effect size was only –15% (Figure 3B and Supplementary 
materials). Even when effect sizes were large and the number 
of time points was moderate (14 pre-intervention and 14 
post-intervention time points), analyses were underpowered 
if sample size per time point was low (Figure 3B and Supple-
mentary materials). Interestingly, little difference was found 
in power following an early or late intervention as compared 
to when the intervention occurred midway through (Figure 4). 
The percentage bias in model coefficients was small, and 
this trended toward zero as sample size increased (Figure 5).
Discussion
Main findings
This study demonstrates that simple rules regarding the num-
ber of time points are not adequate by themselves to denote 
an ITS analysis as sufficiently powered. Other factors such 
as the sample size per time point, expected effect size, loca-
Figure 2 Empiracle power to detect a relative 34% reduction in outcome, where mean pre-intervention incidence is 3.5%: by the number of time points and mean sample 
size per time point: (A) slope change (B) step change.
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tion of intervention in the time series, and pre-intervention 
trends need to be considered. For example, in our case study 
where mean pre-intervention level of outcome was 3.5%, to 
achieve 80% power to detect a relative 34% post-intervention 
step change reduction, with 14 pre- and 14 post-intervention 
time points, one needed over 1,000 subjects per time point 
(ie, >28,000 total subjects), which may or may not be realistic 
for a given study. However, three pre- and post-intervention 
Figure 3 Empirical power in the case studya (stratified by effect size) to detect an intervention resulting in (A) a slope change or (B) step change.
Note: aAssuming a mean pre-intervention outcome of 3.5%, mid-time series intervention, and 28 total time points.
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Figure 4 Empirical power in the case studya (stratified by intervention location) to detect an intervention resulting in (A) a slope change or (B) step change.
Note: aAssuming a mean pre-intervention outcome of 3.5%, 28 total time points, and an average 34% relative reduction post intervention (early/late slope changes were 
identical to midway scenario, therefore, achieved a different effect size).
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time points were equally sufficient to achieve 80% power 
in relatively rare situations of large intervention effect sizes 
combined with very large sample sizes per time point (Sup-
plementary materials). These results underline the importance 
of robust pre-study sample size planning. Estimates arising 
from scenarios with a very small n were only slightly biased, 
which disappeared as n increased (Figure 3).
That power increases as N increases is an expected find-
ing and has previously been shown for fixed ratios of effect 
size to the SD of the time series.10,26 However, we in this 
study addressed the previously undescribed trade-off between 
N and n. This is an important consideration and a helpful 
development. First, the SD of a given number of repeated 
population-level outcome measures may likely be difficult 
for applied researchers to estimate in advance of a proposed 
ITS study. Second, exploring this trade-off between N and n 
informs to what extent it may be beneficial (in terms of power) 
when generating an aggregate ITS dataset to sacrifice sample 
size per time point to increase the number of time points (or 
vice versa). It allows a combination of N and n to be selected 
to optimize power. Although the exact nuances of this unique 
trade-off were scenario specific, in most cases only very little 
gain in power was achieved when a time series was lengthened 
at the expense of time point sample size, although gains were 
more noticeable where a very short time series was lengthened.
To the best of our knowledge, a differential power accord-
ing to whether an intervention impact is mediated via a slope 
or step change has not previously been investigated. We 
found that power was greater in slope change scenarios, a 
likely explanation being that our effect size was the average 
difference between post-intervention values and counterfac-
tuals, which in the case of slope change scenarios continued 
to increase as per the pre-intervention slope and therefore 
made detection of a change more probable.
Within scenarios with a slope change, we found power 
to be greater in settings with a balanced number of pre-
intervention and post-intervention time points (as opposed 
to earlier/later interventions), while the location of the inter-
vention had little impact on power to detect step changes and 
was even marginally greater when the intervention occurred 
early. Although this was unexpected, it is not without some 
support from previous work.10
limitations
Our study is subject to various limitations. Each time point 
was a cumulative incidence, and given that individual sub-
jects/patients could only be included in a single time point, 
we treated time points to be independent. As such, we did not 
explore what impact autocorrelation may have on estimates, 
although this remains a subject for further investigation. 
Despite the availability of ITS approaches that explicitly 
model autocorrelation, such as autoregressive integrated 
moving average (ARIMA) models,27 it would seem that 
where the assumptions of OLS regression are met then this 
is preferable for epidemiological studies where the goal is 
likely to be causal inference rather than future prediction. 
Indeed, while autocorrelation needs to be addressed where 
present, it has been noted that in epidemiological studies it 
can often be accounted for by controlling for other variables,2 
and interestingly of a recent review of over 200 drug utiliza-
Figure 5 Percentage bias in estimates of intervention impact in the case studya: stratified by the nature of impact.
Note: aAssuming a mean pre-intervention outcome of 3.5%, total of 28 time points, and an average 34% relative reduction post intervention.
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tion studies implementing ITS analysis, 50% were found to 
use segmented linear regression.1 Specification of ARIMA 
models are frequently cited to require a minimum of 50 time 
points,28 with >100 being preferable,27 yet it is common to 
have less than this minimum available in epidemiology con-
texts using routinely collected data.10,21,23,29 For these reasons, 
our focus in this study was on “short” time series where we 
considered 50 time points as a maximum and used Durbin–
Watson statistics to confirm that first-order autocorrelation 
was not present. Previous work investigated the relationship 
between the number of time points and power in the presence 
of autocorrelation,10,30 where positive autocorrelation has 
been shown to reduce power and negative autocorrelation 
to increase power.10 Similarly, we did not consider season-
ality nor situations where there may be a delay or waning 
intervention effect.
Another limitation is that our definition of effect size 
as the difference between post-intervention time points 
and counterfactual time points (ie, what would have been 
observed had pre-intervention level/slope continued unin-
terrupted) involves extrapolation and therefore uncertainty. 
While this is often done in practice, with uncertainty of model 
estimates expressed using CIs,22 there is still the assumption 
that pre-intervention trends would have continued unchanged.
We only investigated scenarios where the repeated out-
come measure is a cumulative incidence (ie, a proportion). 
This is a common epidemiological measure, but incorporat-
ing other common measures such as person-year rates, means 
(eg, length of hospital stay or drug doses prescribed), and 
frequencies is a logical next step and remains the subject for 
imminent further investigation.
Strengths
The disentangling of N and n is a key strength and novel 
aspect of the current study, as is the separate consideration 
of post-intervention step and slope changes. Although we did 
not investigate the impact of varying all of the parameters 
defined, the development and inclusion of a Stata program 
are important features of the investigation, facilitating 
researchers to estimate sample size requirements for future 
ITS studies in similar applications and thereby promoting 
the avoidance of carrying out underpowered analyses. We 
are currently working on using this tool as the basis for an 
online calculator. It is also worth mentioning that we based 
the parameter values for our case study on a “real-world” 
clinical scenario20 to increase the applicability of the findings, 
rather than starting from arbitrary parameter values.
Conclusion
Multiple factors influence the power of OLS ITS analysis, 
and these should be collectively taken into account when 
considering the feasibility of a proposed ITS study. We have 
demonstrated how a simulation approach can be used to 
estimate the power available within specific ITS scenarios 
and provide Stata code to facilitate pre-analysis sample size 
planning of future ITS studies within similar applications.
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